Nicholas Shorts
-
News
New Drug Discovered May Help Against Memory Loss in Alzheimer’s Disease
A new drug discovered through an analysis collaboration between the University at Buffalo and Tetra Therapeutics could shield against memory…
Read More » -
News
FDA Has Fast Track Designation for The Development of Farxiga (Dapagliflozin)
The F.D.A. has awarded Fast Track designation for the development of AstraZeneca – Farxiga (dapagliflozin) to delay the progressions of…
Read More » -
News
Astrazeneca Announced Positive Results from The Landmark Part III DAPA-HF Trial
AstraZeneca announced positive results from the landmark Part III DAPA-HF trial which confirmed that Farxiga (dapagliflozin) met the primary composite…
Read More » -
News
FDA Approved Pretomanid Tablets in Combination with Bedaquiline and Linezolid for TB
The US Food and Drug Administration authorized Pretomanid Tablets in combination with bedaquiline and linezolid for the remedy of a…
Read More » -
News
Bayer AG Buys BlueRock Therapeutics to Modify Cell Therapy
Bayer AG and BlueRock Therapeutics declared an agreement under which Bayer will acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology…
Read More » -
News
FDA Approved Turalio Capsules for Treatment of Tenosynovial Giant Cell Tumor
The Food and Drug Administration approved Turalio (pexidartinib) capsules for the treatment of adult sufferers with symptomatic tenosynovial giant cell…
Read More » -
News
Price Tag for A Life Costs – $2.1 Million
When the Food and Drug Administration (FDA) accepted Zolgensma, a lifesaving medication to treat spinal muscular atrophy, parents of younger kids…
Read More » -
Pharma
MVASI™ (bevacizumab-awwb) and KANJINTITM (trastuzumab-anns) Now Available in US
Amgen and Allergan plc proposed that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin®…
Read More » -
News
FDA Authorized Multiple Applications for First Generics of Lyrica
U.S. Food and Drug Administration authorized multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain…
Read More » -
News
Boehringer Ingelheim to Purchase All Shares of AMAL Therapeutics SA to Concentrate On Novel Cancer Vaccine
Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company concentrate on cancer…
Read More »